Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2009

Innocenti Federico, Kroetz Deanna L, Schuetz Erin, Dolan M Eileen, Ramírez Jacqueline, Relling Mary, Chen Peixian, Das Soma, Rosner Gary L, Ratain Mark J

Abstract excerpt

PURPOSE: We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in irinotecan (CPT-11) pharmacokinetics and neutropenia in cancer patients. PATIENTS AND METHODS: Pharmacokinetic, genetic, and clinical data were obtained from 85 advanced cancer patients treated with single-agent CPT-11 every 3 weeks at doses of 300 mg/m(2) (n = 20) and 350 mg/m(2) (n =...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Irinotecan
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bilirubin

Share to Glucuronides

Share to Hepatocyte Nuclear Factor 1-alpha

Share to Liver-Specific Organic Anion Transporter 1

Share to Multidrug Resistance-Associated Protein 2

Share to Organic Anion Transporters

Source

Open in PubMed Open full text

Identifiers

PMID: 19349540
DOI: 10.1200/JCO.2008.20.6300
PMCID: PMC2690389

Genes

ABCC1
ABCB1
ABCC2
APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.PMID 19349540Read ↗

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.Semantic proximity Read ↗

Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.Semantic proximity Read ↗

Pharmacogenetics of irinotecan metabolism and transport: an update.Semantic proximity Read ↗

Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.